Multidisciplinary approach in diagnosis of lung carcinoma

Experimental Oncology

Volumn 32, Issue 2, 2010, Pages 111-113

  Kontic, M ^a   Stojsic, J ^a   Kacar Kukric, V ^a   Jekic, B ^a   Bunjevacki, V ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Diagnosis; Immunophenotype; Large cell lung carcinoma; Oncogenetic

Indexed keywords

3 AMINO 9 ETHYLCARBAZOLE; AMINE; BIOLOGICAL MARKER; BIOTIN; CD56 ANTIGEN; CD57 ANTIGEN; CHROMOGRANIN A; CYTOKERATIN AE1; CYTOKERATIN AE3; DIAMINOBENZIDINE; EPITHELIAL MEMBRANE ANTIGEN; GENE PRODUCT; NERVE CELL ADHESION MOLECULE; NEURON SPECIFIC ENOLASE; PROTEIN GENE PRODUCT 9.5; STREPTAVIDIN; SYNAPTOPHYSIN; THYROGLOBULIN; THYROID TRANSCRIPTION FACTOR 1; UNCLASSIFIED DRUG;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CASE REPORT; CODON; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DNA SEQUENCE; EXON; GENE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LUNG CARCINOMA; MALE; MORPHOLOGY; NONHODGKIN LYMPHOMA; P53 GENE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; TISSUE SECTION; TUMOR DIFFERENTIATION;

BASE SEQUENCE; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHOMA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77954618493     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Przygodzki RM, Finkelstein SD, Langer JC, et al. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors: correlation with histological subtype and clinical outcome. Am J Pathol 1996; 148: 1531-41.
2. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
3. Li Z, Wu J, Yang D, et al. Large cell carcinoma of lung: analysis of CT signs and review of the literature. Chinese-German J Clin Oncol 2006; 5: 309-11.
4. Padua RA, Guinn BA, Al-Sabah AI, et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 1998; 12: 887-92.
5. Akata S, Okada S, Maeda J, et al. Computed tomographic findings of large cell neuroendocrine carcinoma of the lung. Clin Imaging 2007; 31: 379-84.
6. Faggiano A, Sabourin J-C, Lumbroso J, et al. Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas. Diagnostic and prognostic features. Cancer 2007; 110: 265-74.
7. Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113: 5-21.
8. Al-Zahrani IH. The value of immunohistochemical expression of TTF-1, CK7 and CK20 in the diagnosis of primary and secondary lung carcinomas. Saudi Med J 2008; 29: 957-61.
9. Travis WD, Brambilla B, Muller-Hermelink K, et al (eds). Pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
10. Stojsic J, Stevic R, Kontic M, et al. Large cell lung carcinoma with unusual imaging feature, immunophenotype and genetic finding. Pathol Oncol Res 2010; DOI 10.1007/s12253-010-9272-8.
11. Stojsic J, Milenkovic B, Radojicic J, et al. Alveolar adenoma - rare lung tumour. Srp Arh Celok Lek 2007; 135: 461-4 (In Serbian).
12. Gao WM, Mady HH, Yu GY, et al. Comparison of p53 mutations between adenocarcinoma and squamous cell carcinoma of the lung: Unique spectra involving G to A transitions and G to T transversions in both histological types. Lung Cancer 2003; 40: 141-50.
13. Ambs S, Bennett WP, Merriam WG, et al. Vascular endothelial growth factor and nitric oxide synthaseexpression in human lung cancer and the relation to p53. Br J Cancer 1998; 78: 233-9.
14. Tomizawa Y, Kohno T, Fujita T, et al. Correlation between the status of the p53 gene and survival in patients with stage I non small cell lung carcinoma. Oncogene 1999; 18: 1007-14.
15. Yamada H, Shinmura K, Yamamura Y, et al. Identification and characterization of a novel germline p53 mutation in a patient with glioblastoma and colon cancer. Int G Cancer 2009; 125: 973-6.
16. Onuki N, Wistuba II, Travis WD, et al. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 1999; 85: 600-7.